SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45).
B. Conrad
No relevant relationships to disclose
N. Harbeck
No relevant relationships to disclose
G. Von Minckwitz
Research Funding - Bayer
M. Wuellner
No relevant relationships to disclose
M. Warm
No relevant relationships to disclose
K. Schwedler
No relevant relationships to disclose
B. Gerber
Honoraria - AstraZeneca; GlaxoSmithKline; Novartis; Roche; Sanofi
Research Funding - Novartis
I. Schrader
No relevant relationships to disclose
H. Eidtmann
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose